Anti-Angiogenesis Therapy of Cancer Cells using 153Sm-Bevasesomab
Purpose: Angiogenesis is essential for tumor growth or metastasis. Avastin is a monoclonal antibody that is used in treating angiogenesis. We labelled this monoclonal antibody with samarium153 and performed in vitro quality control tests as a first step in the production of a new radiopharmaceutical.
Material and Methods: For a successful radiolabeling, we chose DOTA-NHS as the bifunctional chelating agent and optimized radiolabeling condition with modifications of the factors such as reaction time and molar ratio which are known to be very critical in radiolabeling. The efficiency and in vitro stability of antibody labelling were determined using thin layer chromatography. The integrity of the radiolabeled antibody was checked by SDS-PAGE. Biodistribution study of 153Sm-DOTA –avastin was carried out in BALB/c mice at 2, 24, 48 and 72 hours after injection. Immunoreactivity and toxicity of the complex were tested on colon cancer cell line by MTT.
Results: The efficiency of antibody labelling was more than 99%. The in vitro stability of the labelled product in human serum after 120h was 78 ±2%. There was no fragmentation in the labelled antibody during SDS-PAGE protocol. The highest of %ID/g was observed in the blood, liver, lungs and spleen. The immunoreactivity of the complex was 89±1.4%. At a concentration of 1 nM, the complex killed 70±3% of SW480 cells. At 1.9 nM, 90±5% of the cells were killed.Discussion: The monoclonal antibody avastin against angiogenesis was effectively radiolabeled with 153Sm. The results showed that the new complex could be considered a promising tracer for noninvasive delineation of angiogenesis.
Dvorak, Harold F., Lawrence F. Brown, Michael Detmar, and Ann M. Dvorak. "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis." The American journal of pathology 146, no. 5 (1995): 1029-1039.
Shibuya, Masabumi. “Structure and Function of VEGF/VEGF-Receptor System Involved in Angiogenesis.” Cell Structure and Function 26, no. 1 (2001): 25–35. doi:10.1247/csf.26.25.
Breier, Georg. “Functions of the VEGF/VEGF Receptor System in the Vascular System.” Seminars in Thrombosis and Hemostasis 26, no. 05 (2000): 553–560. doi:10.1055/s-2000-13212.
Carmeliet, Peter. “VEGF as a Key Mediator of Angiogenesis in Cancer.” Oncology 69, no. 3 (2005): 4–10. doi:10.1159/000088478.
Rüegg, Curzio, Meriem Hasmim, Ferdy J. Lejeune, and Gian Carlo Alghisi. “Antiangiogenic Peptides and Proteins: From Experimental Tools to Clinical Drugs.” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1765, no. 2 (April 2006): 155–177. doi:10.1016/j.bbcan.2005.09.003.
Mitra, Amitava, Anjan Nan, John C. Papadimitriou, Hamidreza Ghandehari, and Bruce R. Line. “Polymer-Peptide Conjugates for Angiogenesis Targeted Tumor Radiotherapy.” Nuclear Medicine and Biology 33, no. 1 (January 2006): 43–52. doi:10.1016/j.nucmedbio.2005.09.005.
Garcia-Barros, M. “Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis.” Science 300, no. 5622 (May 16, 2003): 1155–1159. doi:10.1126/science.1082504.
Hsu, Jerry Y., and Heather A. Wakelee. “Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor.” BioDrugs 23, no. 5 (October 2009): 289–304. doi:10.2165/11317600-000000000-00000.
Grothey, Axel, and Lee M. Ellis. “Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies.” The Cancer Journal 14, no. 3 (May 2008): 170–177. doi:10.1097/ppo.0b013e318178d9de.
Karagiannis, Tom C. "Comparison of different classes of radionuclides for potential use in radioimmunotherapy." Hell J Nucl Med 10, no. 2 (2007): 82-8.
Khorami-Moghadam, Alireza, Amir Jalilian, Kamal Yavari, Bahram Bolouri, Ali Bahrami-Samani, and Mohammad Ghannadi-Maragheh. "Production and quality control of [166Ho]-DOTA-bevacizumab for therapeutic applications." Journal of Radioanalytical and Nuclear Chemistry 292, no. 3 (2012): 1065-1073.
Xiao, Jie, Xiaobo Xu, Xiao Li, Yanli Li, Guobing Liu, Hui Tan, Hua Shen, Hongcheng Shi, and Dengfeng Cheng. “Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer.” Molecules 21, no. 10 (September 30, 2016): 1308. doi:10.3390/molecules21101308.
Fani, M, S Vranjes, S.C Archimandritis, S Potamianos, S Xanthopoulos, P Bouziotis, and A.D Varvarigou. “Labeling of Monoclonal Antibodies with 153Sm for Potential Use in Radioimmunotherapy.” Applied Radiation and Isotopes 57, no. 5 (November 2002): 665–674. doi:10.1016/s0969-8043(02)00181-1.
Fani, Melpomeni, Stavros Xanthopoulos, Spyridon C. Archimandritis, Nikolaos Stratis, Penelope Bouziotis, George Loudos, and Alexandra D. Varvarigou. "Biodistribution and scintigraphic studies of 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy." Anticancer research 23, no. 3A (2003): 2195-2199.
Kraeber-Bodéré, Françoise, Anil Mishra, Philippe Thédrez, Alain Faivre-Chauvet, Manuel Bardiès, S. Imai, Jean Le Boterff, and Jean-François Chatal. “Pharmacokinetics and Biodistribution of Samarium-153-Labelled OC125 Antibody Coupled to CITCDTPA in a Xenograft Model of Ovarian Cancer.” European Journal of Nuclear Medicine 23, no. 5 (May 1996): 560–567. doi:10.1007/bf00833392.
Izard, M. E., G. R. Boniface, K. L. Hardiman, M. W. Brechbiel, O. A. Gansow, and K. Z. Walker. “An Improved Method for Labeling Monoclonal Antibodies with Samarium-153: Use of the Bifunctional Chelate 2-(p-Isothiocyanatobenzyl)-6-Methyldiethylenetriaminepentaacetic Acid.” Bioconjugate Chemistry 3, no. 4 (July 1992): 346–350. doi:10.1021/bc00016a015.
Pippin, C. Greg, Tammy A. Parker, Thomas J. McMurry, and Martin W. Brechbiel. “Spectrophotometric Method for the Determination of a Bifunctional DTPA Ligand in DTPA-Monoclonal Antibody Conjugates.” Bioconjugate Chemistry 3, no. 4 (July 1992): 342–345. doi:10.1021/bc00016a014.
Adler, Mark J., and Dimiter S. Dimitrov. “Therapeutic Antibodies Against Cancer.” Hematology/Oncology Clinics of North America 26, no. 3 (June 2012): 447–481. doi:10.1016/j.hoc.2012.02.013.
Garnock-Jones, Karly P., Gillian M. Keating, and Lesley J. Scott. “Trastuzumab.” Drugs 70, no. 2 (January 2010): 215–239. doi:10.2165/11203700-000000000-00000.
Dotan, Efrat, Charu Aggarwal, and Mitchell R. Smith. "Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma." Pharmacy and Therapeutics 35, no. 3 (2010): 148.
Arjaans, Marlous, Carolina P. Schröder, Sjoukje F. Oosting, Urania Dafni, Josée E. Kleibeuker, and Elisabeth G.E. de Vries. “VEGF Pathway Targeting Agents, Vessel Normalization and Tumor Drug Uptake: From Bench to Bedside.” Oncotarget 7, no. 16 (January 14, 2016). doi:10.18632/oncotarget.6918.
Aaron P. B.,Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Review, vol.27, no.3, (2008), p. 415–434.
Zhao, Y., and A. A. Adjei. “Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.” The Oncologist 20, no. 6 (May 22, 2015): 660–673. doi:10.1634/theoncologist.2014-0465.
Chong, G., and N.C. Tebbutt. “Using Bevacizumab with Different Chemotherapeutic Regimens in Metastatic Colorectal Cancer: Balancing Utility with Low Toxicity.” Therapeutic Advances in Medical Oncology 2, no. 5 (July 14, 2010): 309–317. doi:10.1177/1758834010375096.
Strickler, J. H., and H. I. Hurwitz. “Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer.” The Oncologist 17, no. 4 (April 1, 2012): 513–524. doi:10.1634/theoncologist.2012-0003.
De Gramont, Aimery, and Eric Van Cutsem. “Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer.” Oncology 69, no. 3 (2005): 46–56. doi:10.1159/000088483.
Yavari, Kamal. "Production and Quality Control of 153Sm-DOTA-Avastin." Journal of Ardabil University of Medical Sciences 11, no. 4 (2011): 380-389.
Nagengast, W. B., E. G. de Vries, G. A. Hospers, N. H. Mulder, J. R. de Jong, H. Hollema, A. H. Brouwers, G. A. van Dongen, L. R. Perk, and M. N. Lub-de Hooge. “In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft.” Journal of Nuclear Medicine 48, no. 8 (August 1, 2007): 1313–1319. doi:10.2967/jnumed.107.041301.
- There are currently no refbacks.
Copyright (c) 2018 Kamal Yavari